A novel inhaled antibiotic that Spexis is developing to treat infections of Pseudomonas aeruginosa — the key bacterial agent of lung infections in cystic fibrosis (CF) — showed a good safety profile in a first trial conducted in healthy volunteers, t
- Date(s)
- January 9, 2023
- Location
- Time
- 20:15 - 20:15
Click on the link below to find out more.
Inhaled Antibiotic for Pseudomonas in CF Shows Safety in Early Trial